NIH drafts policy on ensuring access to new drugs funded by taxpayers

The NIH has pro­posed re­quir­ing bio­phar­ma com­pa­nies or li­censees to sub­mit plans for how pa­tients will ac­cess drugs or de­vices that are de­vel­oped with the help of tax­pay­er fund­ing.

Tues­day’s pro­pos­al is part of a wider push from the Biden ad­min­is­tra­tion to low­er pre­scrip­tion drug prices, built off the pas­sage of the drug price ne­go­ti­a­tions in the In­fla­tion Re­duc­tion Act, which Biden has been cam­paign­ing on. Biden pre­vi­ous­ly drew bi­par­ti­san push­back for a plan to ex­er­cise the gov­ern­ment’s so-called march-in rights when drug prices rise too high.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.